Prescient Therapeutics Accelerates PTX-100 Trial Enrolment and Appoints New CMO
Prescient Therapeutics boosted enrolment in its PTX-100 Phase 2a trial to 28 patients and appointed Dr Rosalind Wilson as Chief Medical Officer, strengthening its clinical leadership as it advances targeted cancer therapies.
- PTX-100 Phase 2a enrolment reaches 28 patients
- Cash reserves stand at $9.03 million at June 30
- Dr Rosalind Wilson appointed Chief Medical Officer
- Global clinical sites in Australia, US, Italy, with France planned
- CEO engages with experts and partners at major biotech conferences
PTX-100 Trial Enrolment Gains Momentum
Prescient Therapeutics (ASX:PTX) has accelerated patient enrolment in its PTX-100 Phase 2a study for Cutaneous T-Cell Lymphoma (CTCL), enrolling 14 patients in the June quarter to reach 26 by quarter-end, with two more patients added shortly after. The trial, which aims to recruit up to 40 patients, now spans clinical sites across Australia, the United States, Italy, and is preparing to open additional sites in France. This global footprint underscores the company’s commitment to advancing its targeted oncology therapy.
Financial Position and R&D Investment
Prescient closed the quarter with $9.03 million in cash and term deposits, up from $7.93 million in March 2026. Net operating cash outflows were $2.87 million, predominantly driven by $1.8 million in research and development and clinical activities. Notably, some R&D expenses related to prior quarters were settled during this period following delayed invoicing from a key clinical services provider. Payments to non-executive directors and related parties amounted to $85,000.
Leadership Boost with New Chief Medical Officer
In a strategic move to bolster clinical development, Prescient appointed Dr Rosalind Wilson as Chief Medical Officer, effective 13 July 2026. Dr Wilson brings over 30 years of global oncology drug development experience, spanning clinical development, regulatory strategy, and executive leadership. She will steer the clinical advancement of PTX-100 and the broader pipeline, including the company's cell therapy platforms.
Engagement at Key Industry Events
CEO James McDonnell actively engaged with haematology experts and potential partners during the quarter. His attendance at the European Hematology Association (EHA) 2026 Congress in Stockholm and the BIO International Convention in San Diego facilitated discussions with leading investigators, including Professor Luigi Zinzani from the University Hospital of Bologna, a principal investigator on the PTX-100 trial. These interactions highlight the ongoing efforts to strengthen clinical collaborations and explore partnership opportunities for Prescient’s novel therapies.
Clinical Outlook and Development Pipeline
Prescient expects to convene a Dose Optimisation Committee meeting before the end of 2026 to review safety data and guide the continuation of the Phase 2a study. Meanwhile, the Phase 1b study remains closed, with one patient continuing on compassionate access. The company is also evaluating further clinical opportunities for PTX-100 in Peripheral T-Cell Lymphoma (PTCL), contingent on dose selection outcomes from the CTCL trial. Beyond PTX-100, Prescient continues to develop its OmniCAR and CellPryme platforms, focusing on enhancing cell therapy efficacy and engaging potential partners to advance these technologies.
Bottom Line?
Prescient’s clinical progress and leadership appointment position it well for key trial milestones, but the upcoming Dose Optimisation Committee decision will be pivotal for PTX-100’s next phase.
Questions in the middle?
- When will the Dose Optimisation Committee announce its recommendations for PTX-100?
- How will Dr Rosalind Wilson’s appointment influence clinical trial strategy and partnerships?
- What timelines and strategies will Prescient pursue for expanding OmniCAR and CellPryme platforms?
